Trials / Unknown
UnknownNCT02281266
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
Investigator Initiated Study of Thymosin in HBV-related HCC
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Jia Fan · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety of Thymalfasin adjuvant therapy in HBV-related HCC after curative resection.
Detailed description
Multi-center, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Thymalfasin Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma After Curative Resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | curative resection | |
| DRUG | thymalfasin | 1.6mg twice a week, 12 months |
| DRUG | nucleoside analog (suggest to use entecavir) |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2018-06-01
- Completion
- 2018-10-01
- First posted
- 2014-11-03
- Last updated
- 2014-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02281266. Inclusion in this directory is not an endorsement.